LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 341 of 535
Next
>>
>
8501 to 8525 of 13356 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
BT-20	GSK1059615	1.11	uM	LJP5	2	E03	72	hr	1097	589	3877	0.1519	-0.2894
BT-20	GSK1059615	1.11	uM	LJP5	3	E03	72	hr	1097	674	3925	0.1717	-0.2328
BT-20	GSK1059615	3.33	uM	LJP6	1	C02	72	hr	1097	456	3610	0.1263	-0.4001
BT-20	GSK1059615	3.33	uM	LJP6	2	C02	72	hr	1097	558	3713	0.1503	-0.3192
BT-20	GSK1059615	3.33	uM	LJP6	3	C02	72	hr	1097	529	3696	0.1431	-0.3406
BT-20	GSK1059615	3.33	uM	LJP5	1	E02	72	hr	1097	387	3735	0.1036	-0.4455
BT-20	GSK1059615	3.33	uM	LJP5	2	E02	72	hr	1097	468	3877	0.1207	-0.3737
BT-20	GSK1059615	3.33	uM	LJP5	3	E02	72	hr	1097	568	3925	0.1447	-0.3010
BT-20	GSK1059615	10	uM	LJP6	1	C01	72	hr	1097	525	3610	0.1454	-0.3488
BT-20	GSK1059615	10	uM	LJP6	2	C01	72	hr	1097	381	3713	0.1026	-0.4519
BT-20	GSK1059615	10	uM	LJP6	3	C01	72	hr	1097	458	3696	0.1239	-0.3926
BT-20	GSK1059615	10	uM	LJP5	1	E01	72	hr	1097	238	3735	0.0637	-0.5789
BT-20	GSK1059615	10	uM	LJP5	2	E01	72	hr	1097	380	3877	0.0980	-0.4413
BT-20	GSK1059615	10	uM	LJP5	3	E01	72	hr	1097	446	3925	0.1136	-0.3871
BT-20	Brivanib	0.04	uM	LJP5	1	P18	72	hr	1097	3511	3735	0.9400	0.9312
BT-20	Brivanib	0.04	uM	LJP5	2	P18	72	hr	1097	3682	3877	0.9495	0.9439
BT-20	Brivanib	0.04	uM	LJP5	3	P18	72	hr	1097	3535	3925	0.9005	0.8893
BT-20	Brivanib	0.12	uM	LJP5	1	P17	72	hr	1097	3273	3735	0.8763	0.8560
BT-20	Brivanib	0.12	uM	LJP5	2	P17	72	hr	1097	3763	3877	0.9704	0.9673
BT-20	Brivanib	0.12	uM	LJP5	3	P17	72	hr	1097	3667	3925	0.9342	0.9273
BT-20	Brivanib	0.37	uM	LJP5	1	P16	72	hr	1097	3608	3735	0.9659	0.9612
BT-20	Brivanib	0.37	uM	LJP5	2	P16	72	hr	1097	3979	3877	1.0261	1.0285
BT-20	Brivanib	0.37	uM	LJP5	3	P16	72	hr	1097	3510	3925	0.8942	0.8820
BT-20	Brivanib	1.11	uM	LJP5	1	P15	72	hr	1097	3382	3735	0.9054	0.8907
BT-20	Brivanib	1.11	uM	LJP5	2	P15	72	hr	1097	3787	3877	0.9766	0.9742

|<
<<
Previous
Page 341 of 535
Next
>>
>
8501 to 8525 of 13356 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)